Bio-Rad Laboratories Class A
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 8,030
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
41% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 54
32% more call options, than puts
Call options by funds: $5.22M | Put options by funds: $3.94M
4% more funds holding
Funds holding: 426 [Q3] → 442 (+16) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 144
4% less capital invested
Capital invested by funds: $6.43B [Q3] → $6.16B (-$266M) [Q4]
2.42% less ownership
Funds ownership: 84.27% [Q3] → 81.85% (-2.42%) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Wells Fargo Brandon Couillard 24% 1-year accuracy 6 / 25 met price target | 13%upside $270 | Equal-Weight Maintained | 17 Apr 2025 |
Financial journalist opinion
